Skip to main content
Top
Published in: Immunologic Research 5/2022

28-06-2022 | Neutropenia | Original Article

The ability of inflammatory markers to recognize infection in cancer patients with fever at admission

Authors: Lubei Rao, Kaijiong Zhang, Huaichao Luo, Shuya He, Yuping Li, Chang Liu, Ying Yang, Dongsheng Wang

Published in: Immunologic Research | Issue 5/2022

Login to get access

Abstract

Infection is one of the main causes of death in cancer patients. Accurate identification of fever caused by infection could avoid unnecessary antibiotic treatment and hospitalization. This study evaluated the diagnostic value of procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and other commonly used inflammatory markers in suspected infected adult cancer patients with fever, for better use of antibiotics. This research retrospective analyzed the clinical data of 102 adult cancer patients with fever and compared the serum levels of commonly used inflammatory markers for different fever reasons. Receiver-operating characteristic (ROC) curve and logistic regression analyses were performed. In adult cancer patients with fever, the serum PCT, CRP, IL-6, and IL-10 levels of infected patients were significantly higher than uninfected patients (median 1.19 ng/ml vs 0.14 ng/ml, 93.11 mg/l vs 56.55 mg/l, 123.74 pg/ml vs 47.35 pg/ml, 8.74 pg/ml vs 3.22 pg/ml; Mann–Whitney p = 0.000, p = 0.009, p = 0.004, p = 0.000, respectively). The ROC area under the curve(AUC) was 0.769 (95% confidence interval (CI) 0.681–0.857; p = 0.000) for PCT, 0.664 (95% CI 0.554–0.775; p = 0.009) for CRP, 0.681(95% CI 0.576–0.785; p = 0.004) for IL-6, and 0.731(95% CI 0.627–0.834; p = 0.000) for IL-10. PCT had specificity of 96.67% and positive predictive value (PPV) of 97.6%, when the cut-off value is set as 0.69 ng/ml. The serum IL-6 and IL-10 levels also had significant differences between the infected and uninfected cancer patients with advanced disease (median 128.92 pg/ml vs 36.40 pg/ml, 8.05 pg/ml vs 2.92 pg/ml; Mann–Whitney p = 0.003, p = 0.001, respectively). For the patients with neutropenia, IL-6 and IL-10 had higher AUC of 0.811 and 0.928, respectively. With a cut-off of 9.10 pg/ml, IL-10 had the highest sensitivity 83.33% and specificity 100%. In adult cancer patients, PCT had the best performance compared to CRP, IL-6, and IL-10 in differentiating infected from uninfected causes of fever, with high specificity and PPV. IL-6 and IL-10 might be useful in cancer patients with severe bloodstream infections and advanced disease. However, for patients with neutropenia, IL-10 might be more valuable than PCT in diagnosing infection.
Literature
1.
go back to reference El Haddad H, Chaftari A, Hachem R, Chaftari P, Raad IJCidaopotIDSoA. Biomarkers of sepsis and bloodstream infections: the role of procalcitonin and proadrenomedullin with emphasis in patients with cancer. 2018;67(6):971-977. El Haddad H, Chaftari A, Hachem R, Chaftari P, Raad IJCidaopotIDSoA. Biomarkers of sepsis and bloodstream infections: the role of procalcitonin and proadrenomedullin with emphasis in patients with cancer. 2018;67(6):971-977.
2.
go back to reference Hensley M, Donnelly J, Carlton E, Prescott HJCcm. Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations. 2019;47(10):1310-1316. Hensley M, Donnelly J, Carlton E, Prescott HJCcm. Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations. 2019;47(10):1310-1316.
3.
go back to reference Moore J, Akinyemiju T, Bartolucci A, Wang H, Waterbor J, Griffin RJJoicm. Mediating effects of frailty indicators on the risk of sepsis after cancer. 2020;35(7):708-719. Moore J, Akinyemiju T, Bartolucci A, Wang H, Waterbor J, Griffin RJJoicm. Mediating effects of frailty indicators on the risk of sepsis after cancer. 2020;35(7):708-719.
4.
go back to reference Kuderer N, Dale D, Crawford J, Cosler L, Lyman GJC. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. 2006;106(10):2258-2266. Kuderer N, Dale D, Crawford J, Cosler L, Lyman GJC. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. 2006;106(10):2258-2266.
5.
go back to reference Williams M, Braun L, Cooper L, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. 2004;8(5):R291–298. Williams M, Braun L, Cooper L, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. 2004;8(5):R291–298.
6.
go back to reference Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw : JNCCN. 2016;14(7):882–913.CrossRef Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw : JNCCN. 2016;14(7):882–913.CrossRef
7.
go back to reference Zheng Y, Chen Y, Yu K, et al. Fatal infections among cancer patients: a population-based study in the United States. Infect Dis Ther. 2021;10(2):871–95.CrossRef Zheng Y, Chen Y, Yu K, et al. Fatal infections among cancer patients: a population-based study in the United States. Infect Dis Ther. 2021;10(2):871–95.CrossRef
8.
go back to reference Kubeček O, Paterová P, Novosadová M. Risk factors for infections, antibiotic therapy, and its impact on cancer therapy outcomes for patients with solid tumors. Life (Basel, Switzerland). 2021;11(12). Kubeček O, Paterová P, Novosadová M. Risk factors for infections, antibiotic therapy, and its impact on cancer therapy outcomes for patients with solid tumors. Life (Basel, Switzerland). 2021;11(12).
9.
go back to reference Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer (Oxford, England : 1990). 2022;38(Suppl 4):S82-87. Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer (Oxford, England : 1990). 2022;38(Suppl 4):S82-87.
10.
go back to reference Penel N, Fournier C, Clisant S, N'Guyen. MJScicojotMAoSCiC. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. 2004;12(8):593-598 Penel N, Fournier C, Clisant S, N'Guyen. MJScicojotMAoSCiC. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. 2004;12(8):593-598
11.
go back to reference Babady NE. Laboratory diagnosis of infections in cancer patients: challenges and opportunities. J Clin Microbiol. 2016;54(11):2635–46.CrossRef Babady NE. Laboratory diagnosis of infections in cancer patients: challenges and opportunities. J Clin Microbiol. 2016;54(11):2635–46.CrossRef
12.
go back to reference Oberhoffer M, Russwurm S, Bredle D, Chatzinicolaou K, Reinhart KJIcm. Discriminative power of inflammatory markers for prediction of tumor necrosis factor-alpha and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points. 2000;S170–174. Oberhoffer M, Russwurm S, Bredle D, Chatzinicolaou K, Reinhart KJIcm. Discriminative power of inflammatory markers for prediction of tumor necrosis factor-alpha and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points. 2000;S170–174.
13.
go back to reference Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001.CrossRef Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001.CrossRef
14.
go back to reference Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncology : Off J Eur Soc Med Oncol. 2019;30(10):1572–9.CrossRef Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncology : Off J Eur Soc Med Oncol. 2019;30(10):1572–9.CrossRef
15.
go back to reference Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050.CrossRef Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050.CrossRef
16.
go back to reference Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. Emerging technologies for molecular diagnosis of sepsis. Clin Microbiol Rev 2018;31(2) Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. Emerging technologies for molecular diagnosis of sepsis. Clin Microbiol Rev 2018;31(2)
17.
go back to reference Blevins SM, Bronze MS. Robert Koch and the ‘golden age’ of bacteriology. Int J Infect Diseases : IJID : Off Publ Int Soc Infect Dis. 2010;14(9):e744-751. Blevins SM, Bronze MS. Robert Koch and the ‘golden age’ of bacteriology. Int J Infect Diseases : IJID : Off Publ Int Soc Infect Dis. 2010;14(9):e744-751.
18.
go back to reference Long B, Koyfman A. Best Clinical practice: blood culture utility in the emergency department. J Emerg Med. 2016;51(5):529–39.CrossRef Long B, Koyfman A. Best Clinical practice: blood culture utility in the emergency department. J Emerg Med. 2016;51(5):529–39.CrossRef
19.
go back to reference Riedel S, Carroll KC. Early identification and treatment of pathogens in sepsis: molecular diagnostics and antibiotic choice. Clin Chest Med. 2016;37(2):191–207.CrossRef Riedel S, Carroll KC. Early identification and treatment of pathogens in sepsis: molecular diagnostics and antibiotic choice. Clin Chest Med. 2016;37(2):191–207.CrossRef
20.
go back to reference Petti CA, Bhally HS, Weinstein MP, et al. Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation. J Clin Microbiol. 2006;44(1):257–9.CrossRef Petti CA, Bhally HS, Weinstein MP, et al. Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation. J Clin Microbiol. 2006;44(1):257–9.CrossRef
21.
go back to reference Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2005;41(11):1677–80.CrossRef Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2005;41(11):1677–80.CrossRef
22.
go back to reference Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. 2001;164(3):396–402. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. 2001;164(3):396–402.
23.
go back to reference Dinarello CJEjoi. Historical insights into cytokines. 2007:S34–45. Dinarello CJEjoi. Historical insights into cytokines. 2007:S34–45.
24.
go back to reference Balkwill F, Mantovani AJL. Inflammation and cancer: back to Virchow? 2001;357(9255):539–545. Balkwill F, Mantovani AJL. Inflammation and cancer: back to Virchow? 2001;357(9255):539–545.
25.
go back to reference Mondal AM, Horikawa I, Pine SR, et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Investig. 2013;123(12):5247–57.CrossRef Mondal AM, Horikawa I, Pine SR, et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Investig. 2013;123(12):5247–57.CrossRef
26.
go back to reference Taniguchi K, Karin MJSii. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. 2014;26(1):54–74. Taniguchi K, Karin MJSii. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. 2014;26(1):54–74.
27.
go back to reference Li N, Grivennikov S, Karin MJCc. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. 2011;19(4):429–431. Li N, Grivennikov S, Karin MJCc. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. 2011;19(4):429–431.
28.
go back to reference Sullivan N, Sasser A, Axel A, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. 2009;28(33):2940–2947. Sullivan N, Sasser A, Axel A, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. 2009;28(33):2940–2947.
29.
go back to reference Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103–7.CrossRef Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103–7.CrossRef
30.
go back to reference Mocellin S, Panelli M, Wang E, Nagorsen D, Marincola FJTii. The dual role of IL-10. 2003;24(1):36–43. Mocellin S, Panelli M, Wang E, Nagorsen D, Marincola FJTii. The dual role of IL-10. 2003;24(1):36–43.
31.
go back to reference Huang S, Xie K, Bucana C, Ullrich S, Bar-Eli MJCcraojotAAfCR. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. 1996;2(12):1969–1979. Huang S, Xie K, Bucana C, Ullrich S, Bar-Eli MJCcraojotAAfCR. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. 1996;2(12):1969–1979.
32.
go back to reference Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10:6.CrossRef Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10:6.CrossRef
33.
go back to reference van der Galiën HT, Loeffen EAH, Miedema KGE, Tissing WJE. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Support Care Cancer : Fff J Multinational Assoc Support Care Cancer. 2018;26(11):3819–26.CrossRef van der Galiën HT, Loeffen EAH, Miedema KGE, Tissing WJE. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Support Care Cancer : Fff J Multinational Assoc Support Care Cancer. 2018;26(11):3819–26.CrossRef
34.
go back to reference Urbonas V, Eidukaitė A, Tamulienė IJC. Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. 2012;57(3):313–315. Urbonas V, Eidukaitė A, Tamulienė IJC. Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. 2012;57(3):313–315.
35.
go back to reference Matzaraki V, Alexandraki K, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. 2007;40:336–342. Matzaraki V, Alexandraki K, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. 2007;40:336–342.
36.
go back to reference Chaftari A, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. 2015;10(7):e0130999. Chaftari A, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. 2015;10(7):e0130999.
37.
go back to reference Allin K, Nordestgaard BJCricls. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. 2011;48(4):155-170. Allin K, Nordestgaard BJCricls. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. 2011;48(4):155-170.
38.
go back to reference Doerflinger M, Haeusler G, Li-Wai-Suen C, et al. Procalcitonin and interleukin-10 may assist in early prediction of bacteraemia in children with cancer and febrile neutropenia. 2021;12:641879. Doerflinger M, Haeusler G, Li-Wai-Suen C, et al. Procalcitonin and interleukin-10 may assist in early prediction of bacteraemia in children with cancer and febrile neutropenia. 2021;12:641879.
39.
go back to reference Fleischhack G, Cipic D, Juettner J, Hasan C, Bode UJIcm. Procalcitonin-a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. 2000:S202–211. Fleischhack G, Cipic D, Juettner J, Hasan C, Bode UJIcm. Procalcitonin-a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. 2000:S202–211.
40.
go back to reference Kallio R, Surcel H, Bloigu A, Syrjälä HJEjoc. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. 2000;36(7):889–894. Kallio R, Surcel H, Bloigu A, Syrjälä HJEjoc. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. 2000;36(7):889–894.
41.
go back to reference Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. 2016;9:469-475 Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. 2016;9:469-475
42.
go back to reference Diness LV, Maraldo MV, Mortensen CE, Mellemgaard A, Larsen FO. Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumours. Dan Med J. 2014;61(12):A4984.PubMed Diness LV, Maraldo MV, Mortensen CE, Mellemgaard A, Larsen FO. Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumours. Dan Med J. 2014;61(12):A4984.PubMed
43.
go back to reference Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136(4):611–5.CrossRef Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136(4):611–5.CrossRef
44.
go back to reference Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99(3):580–8.CrossRef Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99(3):580–8.CrossRef
45.
go back to reference Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. Onco Targets Ther. 2016;9:469–75.PubMedPubMedCentral Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. Onco Targets Ther. 2016;9:469–75.PubMedPubMedCentral
46.
go back to reference Ittner L, Born W, Rau B, Steinbach G, Fischer JJEjoe. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. 2002;147(6):727-731. Ittner L, Born W, Rau B, Steinbach G, Fischer JJEjoe. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. 2002;147(6):727-731.
47.
go back to reference Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(3):861–8.CrossRef Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(3):861–8.CrossRef
48.
go back to reference Ichikawa K, Watanabe S, Miura S, et al. Prognostic significance of procalcitonin in small cell lung cancer. 2022;11(1):43-52 Ichikawa K, Watanabe S, Miura S, et al. Prognostic significance of procalcitonin in small cell lung cancer. 2022;11(1):43-52
49.
go back to reference Ghillani P, Motté P, Troalen F, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. 1989;49(23):6845-6851 Ghillani P, Motté P, Troalen F, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. 1989;49(23):6845-6851
50.
go back to reference Vincenzi B, Fioroni I, Pantano F, et al. Procalcitonin as diagnostic marker of infection in solid tumors patients with fever. Sci Rep. 2016;6:28090.CrossRef Vincenzi B, Fioroni I, Pantano F, et al. Procalcitonin as diagnostic marker of infection in solid tumors patients with fever. Sci Rep. 2016;6:28090.CrossRef
51.
go back to reference Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34(1):17–60.CrossRef Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34(1):17–60.CrossRef
52.
go back to reference Opota O, Jaton K, Greub G. Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood. Clin Microbiol Infect : Off Publ Eur Soc Clin Microbiol Infect Dis. 2015;21(4):323–31.CrossRef Opota O, Jaton K, Greub G. Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood. Clin Microbiol Infect : Off Publ Eur Soc Clin Microbiol Infect Dis. 2015;21(4):323–31.CrossRef
53.
go back to reference Garcia RA, Spitzer ED, Beaudry J, et al. Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections. Am J Infect Control. 2015;43(11):1222–37.CrossRef Garcia RA, Spitzer ED, Beaudry J, et al. Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections. Am J Infect Control. 2015;43(11):1222–37.CrossRef
54.
go back to reference Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents. 2007;30(Suppl 1):S7-15.CrossRef Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents. 2007;30(Suppl 1):S7-15.CrossRef
55.
go back to reference Riedel S, Carroll KC. Blood cultures: key elements for best practices and future directions. J Infect Chemother : Off J Japan Soc Chemother. 2010;16(5):301–16.CrossRef Riedel S, Carroll KC. Blood cultures: key elements for best practices and future directions. J Infect Chemother : Off J Japan Soc Chemother. 2010;16(5):301–16.CrossRef
56.
go back to reference Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. 2014;21(1):104-106 Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. 2014;21(1):104-106
57.
go back to reference Vassallo M, Michelangeli C, Fabre R, et al. Procalcitonin and C-reactive protein/procalcitonin ratio as markers of infection in patients with solid tumors. Front Med (Lausanne). 2021;8: 627967.CrossRef Vassallo M, Michelangeli C, Fabre R, et al. Procalcitonin and C-reactive protein/procalcitonin ratio as markers of infection in patients with solid tumors. Front Med (Lausanne). 2021;8: 627967.CrossRef
58.
go back to reference Covino M, Manno A, De Matteis G, et al. Prognostic role of serum procalcitonin measurement in adult patients admitted to the emergency department with fever. Antibiotics 2021;10(7). Covino M, Manno A, De Matteis G, et al. Prognostic role of serum procalcitonin measurement in adult patients admitted to the emergency department with fever. Antibiotics 2021;10(7).
59.
go back to reference Goodlet K, Cameron E, Nailor MJOfid. Low sensitivity of procalcitonin for bacteremia at an academic medical center: a cautionary tale for antimicrobial stewardship. 2020;7(4):ofaa096. Goodlet K, Cameron E, Nailor MJOfid. Low sensitivity of procalcitonin for bacteremia at an academic medical center: a cautionary tale for antimicrobial stewardship. 2020;7(4):ofaa096.
60.
go back to reference Chaftari P, Qdaisat A, Chaftari A, et al. Prognostic value of procalcitonin, c-reactive protein, and lactate levels in emergency evaluation of cancer patients with suspected infection. 2021;13(16). Chaftari P, Qdaisat A, Chaftari A, et al. Prognostic value of procalcitonin, c-reactive protein, and lactate levels in emergency evaluation of cancer patients with suspected infection. 2021;13(16).
61.
go back to reference Lai L, Lai Y, Wang H, et al. Diagnostic accuracy of procalcitonin compared to c-reactive protein and interleukin 6 in recognizing gram-negative bloodstream infection: a meta-analytic study. 2020;2020:4873074. Lai L, Lai Y, Wang H, et al. Diagnostic accuracy of procalcitonin compared to c-reactive protein and interleukin 6 in recognizing gram-negative bloodstream infection: a meta-analytic study. 2020;2020:4873074.
62.
go back to reference Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London, England). 1993;341(8844):515–8.CrossRef Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London, England). 1993;341(8844):515–8.CrossRef
63.
go back to reference Debiane L, Hachem R, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. 2014;42(12):2500–2507. Debiane L, Hachem R, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. 2014;42(12):2500–2507.
64.
go back to reference Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. 2005;94(6):767–773. Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. 2005;94(6):767–773.
65.
go back to reference Xia T, Xu X, Zhao N, et al. Comparison of the diagnostic power of cytokine patterns and procalcitonin for predicting infection among paediatric haematology/oncology patients. 2016;22(12):996-1001. Xia T, Xu X, Zhao N, et al. Comparison of the diagnostic power of cytokine patterns and procalcitonin for predicting infection among paediatric haematology/oncology patients. 2016;22(12):996-1001.
66.
go back to reference Shomali W, Hachem R, Chaftari A, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? 2012;118(23):5823–5829. Shomali W, Hachem R, Chaftari A, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? 2012;118(23):5823–5829.
Metadata
Title
The ability of inflammatory markers to recognize infection in cancer patients with fever at admission
Authors
Lubei Rao
Kaijiong Zhang
Huaichao Luo
Shuya He
Yuping Li
Chang Liu
Ying Yang
Dongsheng Wang
Publication date
28-06-2022
Publisher
Springer US
Keyword
Neutropenia
Published in
Immunologic Research / Issue 5/2022
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-022-09299-4

Other articles of this Issue 5/2022

Immunologic Research 5/2022 Go to the issue